Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researchers to begin drug development projects for rare and neglected diseases

Researchers to begin drug development projects for rare and neglected diseases

Tigecycline antibiotic shows promise against leukemia

Tigecycline antibiotic shows promise against leukemia

Cord Blood America third quarter revenues increase 56% to $1.49 million

Cord Blood America third quarter revenues increase 56% to $1.49 million

EntreMed third quarter net loss decreases to $1.3 million

EntreMed third quarter net loss decreases to $1.3 million

New stem cell technique hopes to replace damaged cells in Parkinson's

New stem cell technique hopes to replace damaged cells in Parkinson's

CCCBD scientist to receive 2011 V Foundation Translational Research Grant

CCCBD scientist to receive 2011 V Foundation Translational Research Grant

Combination of azacitidine and entinostat shows promise against NSCLC

Combination of azacitidine and entinostat shows promise against NSCLC

New epigenetic therapy may treat recurrent metastatic NSCLC

New epigenetic therapy may treat recurrent metastatic NSCLC

Ligand third quarter total revenues decrease to $5.7 million

Ligand third quarter total revenues decrease to $5.7 million

CytRx reports net loss of $0.6 million for third quarter 2011

CytRx reports net loss of $0.6 million for third quarter 2011

Micromet third quarter total revenues decrease to $4.5 million

Micromet third quarter total revenues decrease to $4.5 million

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics first quarter GAAP net loss increases to $14.5M

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

PKM2 enzyme has important non-metabolic functions in cancer formation

PKM2 enzyme has important non-metabolic functions in cancer formation

Sleeping Beauty transposon system plays a vital role in investigating colorectal cancer pathway

Sleeping Beauty transposon system plays a vital role in investigating colorectal cancer pathway

Asuragen announces data from microRNA biomarker study on pancreatic cancer

Asuragen announces data from microRNA biomarker study on pancreatic cancer

Scientists discover alternative mechanism for extension of telomeres

Scientists discover alternative mechanism for extension of telomeres

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.